These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9548450)

  • 21. Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer.
    Sun H; Xin J; Lu Z; Wang N; Liu N; Guo Q
    Cell Physiol Biochem; 2013; 32(5):1528-40. PubMed ID: 24335178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma.
    Ioachim E; Charchanti A; Stavropoulos NE; Skopelitou A; Athanassiou ED; Agnantis NJ
    Histol Histopathol; 2000 Jul; 15(3):721-7. PubMed ID: 10963116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.
    Stadler WM; Lerner SP; Groshen S; Stein JP; Shi SR; Raghavan D; Esrig D; Steinberg G; Wood D; Klotz L; Hall C; Skinner DG; Cote RJ
    J Clin Oncol; 2011 Sep; 29(25):3443-9. PubMed ID: 21810677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
    Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
    Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
    Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
    Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Interaction between p53 and MDM2 in human lung cancer cells].
    Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
    Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
    Jahnson S; Karlsson MG
    Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
    Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H
    Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
    Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
    Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
    J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM2 expression in areca quid chewing-associated oral squamous cell carcinomas in Taiwan.
    Huang JS; Ho TJ; Chiang CP; Kok SH; Kuo YS; Kuo MY
    J Oral Pathol Med; 2001 Jan; 30(1):53-8. PubMed ID: 11140901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of p53, MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis.
    García-Tello A; Angulo JC; Andrés G; Ramón de Fata F; Sánchez-Chapado M; López JI
    Actas Urol Esp; 2014 Oct; 38(8):506-14. PubMed ID: 24702909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
    Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
    Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer.
    Matsumoto H; Wada T; Fukunaga K; Yoshihiro S; Matsuyama H; Naito K
    Jpn J Clin Oncol; 2004 Mar; 34(3):124-30. PubMed ID: 15078907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.
    Burch PA; Richardson RL; Cha SS; Sargent DJ; Pitot HC; Kaur JS; Camoriano JK
    J Urol; 2000 Nov; 164(5):1538-42. PubMed ID: 11025699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.